Table 1.
Clinical data are presented for group 1 dogs in each ACVIM Heart disease stage
| Variable | ACVIM heart disease stage | Adjusted P value for post hoc significance if indicated | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage B1 (n = 9) | Stage B2 (n = 62) | Stage C (n = 62) | Stage D (n = 16) | P value | B1 versus B2 | B1 versus C | B1 versus D | B2 versus C | B2 versus D | C versus D | |
| Age (years) | 11.1 (9.1‐12.1) | 10.1 (8.6‐11.8) | 10.3 (8.0‐12.2) | 10.5 (9.8‐12.0) | .7 | ||||||
| Weight (kg) | 10.5 (7.6‐14.9) | 9.9 (7.6‐13.3) | 8.1 (4.8‐18.8) | 6.9 (6.2‐10.9) | .2 | ||||||
| Underlying disease | 9 DMVD 0 DCM | 57 DMVD 5 DCM | 49 DMVD 13 DCM | 16 DMVD 0 DCM | |||||||
| Systolic Blood Pressure (mmHg) | 140 (125‐170) | 140 (125‐145) | 120 (110‐140) | 110 (100‐133) | .002 | .17 | .03 | .005 | .13 | .03 | .17 |
| Furosemide dosage (mg/kg/day) | n = 61; 3.5 (2.9‐4.5) | n = 10; 8.1 (6.0‐8.9) | <.0001 | ||||||||
| Torsemide dosage (mg/kg/day) | n = 1; 0.68 | n = 6; 1.3 (1.2‐1.5) | ND | ||||||||
| ACE inhibitor dosage (mg/kg/day) | n = 39; 0.83 (0.72‐1.0) | n = 51; 0.85 (0.71‐1.0) | n = 15; 0.98 (0.83‐1.2) | .02 | .8 | .03 | .02 | ||||
| Pimobendan dosage (mg/kg/day) | n = 25; 0.57 (0.50‐0.74) | n = 62; 0.73 (0.6‐1.0) | n = 16; 1.9 (1.4‐3.1) | <.0001 | .04 | <.0001 | <.0001 | ||||
| Spironolactone dosage (mg/kg/day) | n = 26; 1.8 (1.6‐2.4) | n = 16; 2.7 (2.1‐3.9) | <.0001 | ||||||||
| Furosemide equivalent dosage (mg/kg/day) | n = 62; 3.53 (2.93‐4.50) | n = 16; 8.90 (7.18‐12.83) | <.0001 | ||||||||
Notes: Overall P value is shown for comparison between stage C and D and for between all groups. Adjusted P value is shown when multiple comparison testing was performed due to overall significance. Data are reported as medians and interquartile ranges.
Abbreviations: ACVIM, American College of Veterinary Internal Medicine, DMVD, degenerative mitral valve disease; DCM, dilated cardiomyopathy; ND, not done.